Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Ophthalmology. 2014 Dec 24;122(4):662–668. doi: 10.1016/j.ophtha.2014.11.006

Fig. 1.

Fig. 1

Changes in symptoms and signs in the subgroups with low or near-normal baseline subbasal nerve fiber length (SNFL) after 4 weeks of treatment with artificial tears, loteprednol etabonate, and loteprednol etabonate/tobramycin as well as during 4 weeks after stopping the treatment.